Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

Executive Summary

The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.

Advertisement

Related Content

Lilly/Loxo Deal Came Together Quickly
How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation
Loxo Links And Colorectal Cancer Data Put Array In M&A Spotlight
J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
Bristol/Celgene Made Perfect Sense, But Doesn’t Promise Big M&A Year, EY Says
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
GSK Embraces PARP Promise With Tesaro Buy
$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel